CD40 ligand-CD40-Interleukin-12 signaling axis (CD40L-CD40-IL12 axis)

The CD40L-driven IL-12 secretion pathway is a critical immune signaling axis that facilitates communication between activated T cells and dendritic cells (DCs). It is initiated when CD40 ligand (CD40L/CD154) on T cells binds to the CD40 receptor on DCs, triggering intracellular signaling through TRAF proteins and the NF-κB pathway [UniProt P25942, P29965]. This activation leads to the robust production and secretion of Interleukin-12 (IL-12), a heterodimeric cytokine essential for bridging innate and adaptive immunity [PMID: 10590718]. IL-12 subsequently drives the differentiation of naive CD4+ T cells into Th1 effectors and enhances the cytotoxic activity of CD8+ T cells and Natural Killer cells [PMID: 11114383]. In oncology, this pathway is targeted by CD40 agonistic antibodies to stimulate anti-tumor immune responses and overcome the immunosuppressive tumor microenvironment [PMID: 35115529]. Conversely, in autoimmune diseases like lupus or rheumatoid arthritis, the pathway is inhibited to prevent pathological Th1-mediated inflammation [PMID: 28351931]. Therapeutic development has faced challenges such as systemic cytokine release syndrome and hepatotoxicity when using potent agonists [PMID: 30635454]. Monitoring serum IL-12 levels and DC maturation markers serves as a key strategy for assessing the efficacy of drugs targeting this axis.

Other names

CD40L-driven IL-12 secretion pathwayCD40-mediated IL-12 productionT-cell-Dendritic cell crosstalk axisCD40L-CD40-IL12 pathway

Agonism of the CD40 receptor to induce IL-12 secretion, or antagonism of the CD40-CD40L interaction to inhibit IL-12 production.